Skip to main content
SpringerLink
Log in
Book cover

Lung Cancer pp 161–175Cite as

Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer

  • Chapter
  • First Online:

  • 2242 Accesses

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

In at least some patients, radiotherapy alone can lead to long-term control of stage III or medically inoperable stage I-II non-small cell lung cancer (NSCLC). Administration of chemotherapy with radiotherapy increases survival rates in stage III NSCLC, and administration of chemotherapy concurrently with radiotherapy is more effective than sequential administration of induction chemotherapy followed later by radiotherapy. Concurrent administration is particularly important for augmenting local control of tumor. Chemotherapy can improve outcome by killing cells that survive radiotherapy, by killing distant micrometastases, and by sensitizing tumor cells to radiation. Radiosensitization has been noted with several classes of systemic agents, including platinums, taxanes, vinca alkaloids, topoisomerase I and II inhibitors, antimetabolites, and agents targeting the epidermal growth factor receptor and HER2/neu. It is anticipated that several other classes of new targeted agents could also play a role in the future. New radiotherapy techniques including intensity-modulated radiation therapy and proton beam therapy have the potential to further improve the outcome, and early clinical trials are underway to optimize the combination of systemic agents with these new radiotherapy options.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Dillman RO, Seagren SL, Propert KJ et al (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323(14):940-945

    Article  PubMed  CAS  Google Scholar 

  2. Auperin A, Le Pechoux C, Pignon JP et al (2006) Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 17(3):473-483

    Article  PubMed  CAS  Google Scholar 

  3. Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17(9):2692-2699

    PubMed  CAS  Google Scholar 

  4. Curran WJ, Scott C, Langer C, et al (2000) Phase III comparison of sequential vs concurrent chemoradiation for patients (Pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol Abstract # 1891.

    Google Scholar 

  5. Woodward W, Cox J (2008) Molecular basis of radiation therapy. In: Mendelsohn J, Howley P, Israel M (eds) The molecular basis of cancer, 3rd edn. Saunders Elsevier, Philadelphia, PA, pp 593-604

    Chapter  Google Scholar 

  6. Milas L, Cox JD (2010) Principles of combining radiation therapy and chemotherapy. In: Cox JD, Ang KK (eds) Radiation oncology: rationale, technique, results, 9th edn. Mosby, St. Louis, MO, pp 102-117

    Google Scholar 

  7. Murray N, Coy P, Pater JL et al (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11(2):336-344

    PubMed  CAS  Google Scholar 

  8. Douple EB, Richmond RC (1980) A review of interactions between platinum coordination complexes and ionizing radiation: implications for cancer therapy. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin: current status and new developments. Academic, New York, pp 125-147

    Google Scholar 

  9. Douple EB, Richmond RC, O’Hara JA, Coughlin CT (1985) Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 12(Suppl A):111-124

    Article  PubMed  CAS  Google Scholar 

  10. Stewart DJ, Leavens M, Maor M et al (1982) Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42(6):2474-2479

    PubMed  CAS  Google Scholar 

  11. Wilkins DE, Ng CE, Raaphorst GP (1996) Cisplatin and low dose rate irradiation in cisplatin resistant and sensitive human glioma cells. Int J Radiat Oncol Biol Phys 36(1):105-111

    Article  PubMed  CAS  Google Scholar 

  12. Richmond RC, Zimbrick JD, Hykes DL (1977) Radiation-induced DNA damage and lethality in E. coli as modified by the antitumor agent cis-dichlorodiammineplatinum (II). Radiat Res 71(2):447-460

    Article  PubMed  CAS  Google Scholar 

  13. Wilson GD, Bentzen SM, Harari PM (2006) Biologic basis for combining drugs with radiation. Semin Radiat Oncol 16(1):2-9

    Article  PubMed  Google Scholar 

  14. Myint WK, Ng C, Raaphorst GP (2002) Examining the non-homologous repair process following cisplatin and radiation treatments. Int J Radiat Biol 78(5):417-424

    Article  PubMed  CAS  Google Scholar 

  15. Raaphorst GP, Wang G, Stewart D, Ng CE (1995) A study of cisplatin-radiosensitization through inhibition of repair of sublethal radiation damage in ovarian carcinoma cells sensitive and resistant to cisplatin. Int J Oncol 7:1373-1378

    PubMed  CAS  Google Scholar 

  16. Richmond RC (1984) Toxic variability and radiation sensitization by dichlorodiammineplatinum(II) complexes in Salmonella typhimurium cells. Radiat Res 99(3):596-608

    Article  PubMed  CAS  Google Scholar 

  17. Stewart DJ, Benjamin RS, Luna M et al (1982) Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol 10(1):51-54

    Article  PubMed  CAS  Google Scholar 

  18. Stewart DJ, Molepo JM, Green RM et al (1995) Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin. Br J Cancer 71(3):598-604

    Article  PubMed  CAS  Google Scholar 

  19. Cross P, Tomiak E, Abgoola O, et al (2005) Pilot study of daily low cisplatin and radiotherapy for medically inoperable stage I non-small cell lung cancer: long term follow up. Eur J Cancer Suppl 3(2):340 (Abstract #1175).

    Google Scholar 

  20. Lochrin C, Goss G, Stewart DJ et al (1999) Concurrent chemotherapy with hyperfractionated accelerated thoracic irradiation in stage III non-small cell lung cancer. Lung Cancer 23(1):19-30

    Article  PubMed  CAS  Google Scholar 

  21. Eapen L, Stewart D, Collins J, Peterson R (2004) Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer. J Urol 172(4 Pt 1):1276-1280

    Article  PubMed  CAS  Google Scholar 

  22. Stewart DJ, Chiritescu G, Dahrouge S, Banerjee S, Tomiak EM (2007) Chemotherapy dose-response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 33(2):101-137

    Article  PubMed  CAS  Google Scholar 

  23. Stewart DJ, Benjamin RS, Zimmerman S et al (1983) Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res 43(2):917-920

    PubMed  CAS  Google Scholar 

  24. Stewart DJ, Mikhael NZ, Nair RC et al (1988) Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol 11(2):152-158

    Article  PubMed  CAS  Google Scholar 

  25. Schaake-Koning C, van den Bogaert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326(8):524-530

    Article  PubMed  CAS  Google Scholar 

  26. Stewart DJ, Molepo JM, Eapen L et al (1994) Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological considerations and results of early studies. Int J Radiat Oncol Biol Phys 28(2):531-542

    Article  PubMed  CAS  Google Scholar 

  27. Begg AC, van der Kolk PJ, Emondt J, Bartelink H (1987) Radiosensitization in vitro by cis-diammine (1, 1-cyclobutanedicarboxylato) platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40). Radiother Oncol 9(2):157-165

    Article  PubMed  CAS  Google Scholar 

  28. Groen HJ, Sleijfer S, Meijer C et al (1995) Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. Br J Cancer 72(6):1406-1411

    Article  PubMed  CAS  Google Scholar 

  29. Ardizzoni A, Boni L, Tiseo M et al (2007) Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99(11):847-857

    Article  PubMed  CAS  Google Scholar 

  30. Toiyama Y, Inoue Y, Hiro J et al (2007) The range of optimal concentration and mechanisms of paclitaxel in radio-enhancement in gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 59(6):733-742

    Article  PubMed  CAS  Google Scholar 

  31. Fukuoka K, Arioka H, Iwamoto Y et al (2001) Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer 34(3):451-460

    Article  PubMed  CAS  Google Scholar 

  32. Edelstein MP, Wolfe LA 3rd, Duch DS (1996) Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 23(2 Suppl 5):41-47

    PubMed  CAS  Google Scholar 

  33. Balcer-Kubiczek EK, Attarpour M, Jiang J, Kennedy AS, Suntharalingam M (2006) Cytotoxicity of docetaxel (Taxotere) used as a single agent and in combination with radiation in human gastric, cervical and pancreatic cancer cells. Chemotherapy 52(5):231-240

    Article  PubMed  CAS  Google Scholar 

  34. Creane M, Seymour CB, Colucci S, Mothersill C (1999) Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer. Int J Radiat Biol 75(6):731-737

    Article  PubMed  CAS  Google Scholar 

  35. Dicker AP, Williams TL, Iliakis G, Grant DS (2003) Targeting angiogenic processes by combination low-dose paclitaxel and radiation therapy. Am J Clin Oncol 26(3):e45-e53

    PubMed  Google Scholar 

  36. Nguyen LN, Munshi A, Hobbs ML, Story MD, Meyn RD (2001) Paclitaxel restores radiation-induced apoptosis in a bcl-2-expressing, radiation-resistant lymphoma cell line. Int J Radiat Oncol Biol Phys 49(4):1127-1132

    Article  PubMed  CAS  Google Scholar 

  37. Fukuoka K, Arioka H, Iwamoto Y et al (2002) Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells. Cancer Chemother Pharmacol 49(5):385-390

    Article  PubMed  CAS  Google Scholar 

  38. Van Rensburg CE, Slabbert JP, Bohm L (2006) Influence of irinotecan and SN-38 on the irradiation response of WHO3 human oesophageal tumour cells under hypoxic conditions. Anticancer Res 26(1A):389-393.

    PubMed  Google Scholar 

  39. Xie X, Sasai K, Shibuya K et al (2000) P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative. Cancer Chemother Pharmacol 45(5):362-368

    Article  PubMed  CAS  Google Scholar 

  40. Kim JS, Amorino GP, Pyo H, Cao Q, Choy H (2002) Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells. Radiother Oncol 62(1):61-67

    Article  PubMed  CAS  Google Scholar 

  41. Ng CE, Bussey AM, Raaphorst GP (1994) Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines. Int J Radiat Biol 66(1):49-57

    Article  PubMed  CAS  Google Scholar 

  42. Omura M, Torigoe S, Kubota N (1997) SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids. Radiother Oncol 43(2):197-201

    Article  PubMed  CAS  Google Scholar 

  43. Tamura K, Takada M, Kawase I et al (1997) Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 88(2):218-223

    Article  PubMed  CAS  Google Scholar 

  44. Haddock MG, Ames MM, Bonner JA (1995) Assessing the interaction of irradiation with etoposide or idarubicin. Mayo Clin Proc 70(11):1053-1060

    Article  PubMed  CAS  Google Scholar 

  45. Giocanti N, Hennequin C, Balosso J, Mahler M, Favaudon V (1993) DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res 53(9):2105-2111

    PubMed  CAS  Google Scholar 

  46. Minehan KJ, Bonner JA (1993) The interaction of etoposide with radiation: variation in cytotoxicity with the sequence of treatment. Life Sci 53(15):PL237-PL242.

    Article  PubMed  CAS  Google Scholar 

  47. Genc M, Castro Kreder N, Barten-van Rijbroek A, Stalpers LJ, Haveman J (2004) Enhancement of effects of irradiation by gemcitabine in a glioblastoma cell line and cell line spheroids. J Cancer Res Clin Oncol 130(1):45-51

    Article  PubMed  CAS  Google Scholar 

  48. Ostruszka LJ, Shewach DS (2000) The role of cell cycle progression in radiosensitization by 2’, 2’-difluoro-2’-deoxycytidine. Cancer Res 60(21):6080-6088

    PubMed  CAS  Google Scholar 

  49. Flanagan SA, Robinson BW, Krokosky CM, Shewach DS (2007) Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers. Mol Cancer Ther 6(6):1858-1868

    Article  PubMed  CAS  Google Scholar 

  50. Wachters FM, van Putten JW, Maring JG, Zdzienicka MZ, Groen HJ, Kampinga HH (2003) Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 57(2):553-562

    Article  PubMed  CAS  Google Scholar 

  51. Rosier JF, Michaux L, Ameye G et al (2003) The radioenhancement of two human head and neck squamous cell carcinomas by 2’-2’ difluorodeoxycytidine (gemcitabine; dFdC) is mediated by an increase in radiation-induced residual chromosome aberrations but not residual DNA DSBs. Mutat Res 527(1-2):15-26

    Article  PubMed  CAS  Google Scholar 

  52. Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ (1998) Radiosensitizing potential of gemcitabine (2’, 2’-difluoro-2’-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 41(4):875-882

    Article  PubMed  CAS  Google Scholar 

  53. Pauwels B, Korst AE, Pattyn GG et al (2003) Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 57(4):1075-1083

    Article  PubMed  CAS  Google Scholar 

  54. Mose S, Class R, Weber HW, Rahn A, Brady LW, Bottcher HD (2003) Radiation enhancement by gemcitabine-mediated cell cycle modulations. Am J Clin Oncol 26(1):60-69

    Article  PubMed  CAS  Google Scholar 

  55. Miao JW, Kong WM, Zhang WH, Niu JW, Deng XH (2004) Mechanistic study of radiosensitization by gemcitabine on human squamous carcinoma cell line of the cervix. Zhonghua Fu Chan Ke Za Zhi 39(5):342-345

    PubMed  Google Scholar 

  56. Pauwels B, Korst AE, Lambrechts HA et al (2006) The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother Pharmacol 58(2):219-228

    Article  PubMed  CAS  Google Scholar 

  57. Fukutome M, Maebayashi K, Nasu S, Seki K, Mitsuhashi N (2006) Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 (“Iressa”) and trastuzumab (“Herceptin”). Int J Radiat Oncol Biol Phys 66(2):528-536

    Article  PubMed  CAS  Google Scholar 

  58. Miyata H, Sasaki T, Kuwahara K, Serikawa M, Chayama K (2006) The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines. Int J Oncol 28(4):915-921

    PubMed  CAS  Google Scholar 

  59. Kim JC, Ali MA, Nandi A et al (2005) Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib. Indian J Biochem Biophys 42(6):358-365

    PubMed  CAS  Google Scholar 

  60. Nakata E, Hunter N, Mason K, Fan Z, Ang KK, Milas L (2004) C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys 59(4):1163-1173

    Article  PubMed  CAS  Google Scholar 

  61. Maddineni SB, Sangar VK, Hendry JH, Margison GP, Clarke NW (2005) Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br J Cancer 92(1):125-130

    Article  PubMed  CAS  Google Scholar 

  62. Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE (2008) Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 14(4):1266-1273

    Article  PubMed  CAS  Google Scholar 

  63. Chinnaiyan P, Huang S, Vallabhaneni G et al (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65(8):3328-3335

    PubMed  CAS  Google Scholar 

  64. Herskovic A, Martz K, al-Sarraf M et al (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326(24):1593-1598

    Article  PubMed  CAS  Google Scholar 

  65. al-Sarraf M, Pajak TF, Cooper JS, Mohiuddin M, Herskovic A, Ager PJ (1990) Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study. J Clin Oncol 8(8):1342-1351

    PubMed  CAS  Google Scholar 

  66. Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091-2098

    Article  PubMed  CAS  Google Scholar 

  67. Eifel PJ, Winter K, Morris M et al (2004) Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 22(5):872-880

    Article  PubMed  Google Scholar 

  68. Sause WT, Scott C, Taylor S et al (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87(3):198-205

    Article  PubMed  CAS  Google Scholar 

  69. Le Chevalier T, Arriagada R, Quoix E et al (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83(6):417-423

    Article  PubMed  Google Scholar 

  70. Zatloukal P, Petruzelka L, Zemanova M et al (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46(1):87-98

    Article  PubMed  Google Scholar 

  71. Fournel P, Robinet G, Thomas P et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23(25):5910-5917

    Article  PubMed  CAS  Google Scholar 

  72. Arriagada R, Le Chevalier T, Quoix E et al (1991) ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d’Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys 20(6):1183-1190

    Article  PubMed  CAS  Google Scholar 

  73. Komaki R, Moughan J, Ang K (2007) RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): correlation between EGFR expression and the patients outcome. Proc Am Soc Ther Radiol Oncol 69:57S

    Google Scholar 

  74. Liu HH, Balter P, Tutt T et al (2007) Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys 68(2):531-540

    Article  PubMed  Google Scholar 

  75. Murshed H, Liu HH, Liao Z et al (2004) Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58(4):1258-1267

    Article  PubMed  Google Scholar 

  76. Yom SS, Liao Z, Liu HH et al (2007) Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68(1):94-102

    Article  PubMed  CAS  Google Scholar 

  77. International Commission on Radiation Units and Measurements (1998) Fundamental Quantities and Units for Ionzing Radiation. (ICRU Report 60), International Commission on Radiation Units and Measurements, Bethesda, MD

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX, 77030, USA

    James D. Cox & David J. Stewart

Authors
  1. James D. Cox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. M. D. Anderson Cancer Center, University of Texas, Holcombe Blvd. 1515, Houston, 77030, U.S.A.

    David J. Stewart

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Cox, J.D., Stewart, D.J. (2010). Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer. In: Stewart, D. (eds) Lung Cancer. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-524-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-524-8_7

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-523-1

  • Online ISBN: 978-1-60761-524-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation